---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-278606"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:43:44.226521+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viatris acquires Oyster Point Pharma and Famy Life Sciences for $700-750M to create ophthalmology franchise

## Summary
- Aggregate purchase price $700-750M cash; Oyster Point at $11/share upfront plus up to $2 CVR; expects Q1 2023 close.
- Sees combined ops adding at least $1B net sales and $500M adj. EBITDA by 2028; expects acquisitions to be adjusted EPS accretive in 2023.
- Reaffirms total pre-tax proceeds from Biocon Biologics and non-core asset divestitures up to ~$9B; plans $1B stock repurchase program in 2023.
- Provides 2024-2028 financial targets: total revenue CAGR ~3%, adj. EBITDA CAGR ~4-5%, adj. EPS CAGR ~mid-teens.
- Ophthalmology division to be led by current Oyster Point CEO Jeff Nau upon closing.

## SEC filing metadata
- accession: 0001193125-22-278606
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000119312522278606/0001193125-22-278606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000119312522278606/d496725d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-278606
- JSON: https://secwatch.observer/filing/0001193125-22-278606.json
- Plain text: https://secwatch.observer/filing/0001193125-22-278606.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.